BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
Key Highlights
- ➤Switched patients’ angioedema-related visits fell 30% per-patient-year after switching to ORLADEYO
- ➤ORLADEYO starters saw all-cause hospitalizations decline 53% in real-world data
- ➤ORLADEYO starters saw angioedema-related emergency visits decline 61%
- ➤No significant reduction differences emerged versus lanadelumab or SC-pdC1-INH
- ➤BioCryst will present new pediatric dosing and navenibart interim data at ACAAI 2026
Expert Statements
Sandra Christiansen, Professor of medicine and director of translational research, US HAEA Angioedema Center at the University of California, San Diego
“These real-world studies add to our understanding of healthcare resource utilization among patients with HAE who either initiate ORLADEYO or switch from another long-term prophylactic therapy”
Sandra Christiansen, Professor of medicine and director of translational research, US HAEA Angioedema Center at the University of California, San Diego
“Patients initiating long-term prophylaxis were found to have comparable reductions in hospitalizations and emergency department visits for ORLADEYO, lanadelumab and subcutaneous plasma-derived C1-inhibitor”
Sandra Christiansen, Professor of medicine and director of translational research, US HAEA Angioedema Center at the University of California, San Diego
“Patients who switched to ORLADEYO from an alternative first-line long-term prophylactic therapy experienced a decrease in their angioedema-related medical visits”
Sandra Christiansen, Professor of medicine and director of translational research, US HAEA Angioedema Center at the University of California, San Diego
“Taken together, these findings support ORLADEYO’s clinical and economic benefits as a long-term prophylactic therapy for HAE”
—Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO(®) from another prophylactic therapy—
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of once-daily ORLADEYO(®) (berotralstat), the first and only targeted oral prophylactic therapy for patients with hereditary angioedema (HAE) aged 2 and older, showing reductions in hospitalizations and emergency department visits following ORLADEYO initiation in patients new to long-term prophylactic therapy (LTP) and in patients switching to ORLADEYO from another LTP.
Get started
Create a free account to read the full story.